Faeth Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Faeth Therapeutics Depreciation & Amortization Growth & History (FTH)
Faeth Therapeutics's depreciation and amortization was $122,000 for fiscal 2025.
View full Faeth Therapeutics company overviewFaeth Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $122,000 | −$429,000 | −77.86% |
| 2024 | 2024-12-31 | $551,000 | −$20,000 | −3.50% |
| 2023 | 2023-12-31 | $571,000 | −$43,000 | −7.00% |
| 2022 | 2022-12-31 | $614,000 | −$71,000 | −10.36% |
| 2021 | 2021-12-31 | $685,000 | $476,000 | +227.75% |
| 2020 | 2020-12-31 | $209,000 | — | — |
Faeth Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $25,000 | −$7,000 | −21.88% |
| Q1 2026 | 2026-03-31 | $29,000 | −$1,000 | −3.33% |
| Q4 2025 | 2025-12-31 | $34,000 | — | — |
| Q3 2025 | 2025-09-30 | $30,000 | −$110,000 | −78.57% |
| Q2 2025 | 2025-06-30 | $32,000 | −$103,000 | −76.30% |
| Q1 2025 | 2025-03-31 | $30,000 | −$107,000 | −78.10% |
| Q3 2024 | 2024-09-30 | $140,000 | $3,000 | +2.19% |
| Q2 2024 | 2024-06-30 | $135,000 | −$3,000 | −2.17% |
| Q1 2024 | 2024-03-31 | $137,000 | −$24,000 | −14.91% |
| Q3 2023 | 2023-09-30 | $137,000 | −$14,000 | −9.27% |
| Q2 2023 | 2023-06-30 | $138,000 | −$6,000 | −4.17% |
| Q1 2023 | 2023-03-31 | $161,000 | $4,000 | +2.55% |
| Q3 2022 | 2022-09-30 | $151,000 | $15,000 | +11.03% |
| Q2 2022 | 2022-06-30 | $144,000 | $22,000 | +18.03% |
| Q1 2022 | 2022-03-31 | $157,000 | $59,000 | +60.20% |
| Q3 2021 | 2021-09-30 | $136,000 | $72,000 | +112.50% |
| Q2 2021 | 2021-06-30 | $122,000 | $70,000 | +134.62% |
| Q1 2021 | 2021-03-31 | $98,000 | $75,000 | +326.09% |
| Q3 2020 | 2020-09-30 | $64,000 | — | — |
| Q2 2020 | 2020-06-30 | $52,000 | — | — |
| Q1 2020 | 2020-03-31 | $23,000 | — | — |
Faeth Therapeutics depreciation and amortization trends
Over the last five fiscal years, Faeth Therapeutics's depreciation and amortization decreased from $209,000 to $122,000, a change of −$87,000. The latest reported quarter, Q2 2026, shows $25,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Faeth Therapeutics source filings ↗